Compare TEX & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | PRAX |
|---|---|---|
| Founded | 1933 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.3B |
| IPO Year | 1994 | 2020 |
| Metric | TEX | PRAX |
|---|---|---|
| Price | $52.83 | $268.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 21 |
| Target Price | $76.09 | ★ $650.00 |
| AVG Volume (30 Days) | ★ 1.4M | 490.3K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $5,421,000,000.00 | N/A |
| Revenue This Year | $50.31 | N/A |
| Revenue Next Year | $7.48 | $39,256.17 |
| P/E Ratio | $253.50 | ★ N/A |
| Revenue Growth | ★ 5.73 | N/A |
| 52 Week Low | $41.70 | $154.46 |
| 52 Week High | $74.69 | $392.70 |
| Indicator | TEX | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 38.80 |
| Support Level | $50.64 | $238.77 |
| Resistance Level | $62.24 | $356.02 |
| Average True Range (ATR) | 2.07 | 12.63 |
| MACD | -0.07 | -0.52 |
| Stochastic Oscillator | 7.66 | 35.55 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.